Tessari Eben, Chief Operating Officer of Kiniksa Pharmaceuticals (KNSA), has demonstrated a clear selling bias in recent months, with no open-market purchases recorded since at least September 2025. SEC filings reveal 12 sales totaling approximately $5.9 million in disclosed value over this four-month period, continuing a broader pattern where Eben's total sell transactions ($13.6 million lifetime) significantly outweigh buys ($4.5 million). The most substantial disposals occurred in early September 2025, including a $3.0 million sale on September 4 paired with $722,394 in option exercises, followed by a $535,731 sale the prior day. Activity tapered in subsequent months but remained consistent, with November featuring a $488,373 sale and December's $500,715 transaction representing the largest single disposal since September.
The transactions frequently involved concurrent option exercises (coded "M"), suggesting Eben is liquidating both vested awards and existing holdings. Notably, all activity centers exclusively on KNSA, where Eben has executed all 44 lifetime trades filed with the SEC. The concentration in a single biopharmaceutical stock, combined with the absence of recent acquisitions, presents a straightforward pattern of gradual divestment. While the sales represent a meaningful reduction in exposure, the continued retention of some position—evidenced by partial dispositions rather than complete exits—indicates ongoing equity participation alongside routine option monetization.
AI-assisted summary